Diversity and origin of rheumatologic autoantibodies
- PMID: 1889043
- PMCID: PMC358198
- DOI: 10.1128/CMR.4.3.256
Diversity and origin of rheumatologic autoantibodies
Abstract
A hallmark of sera from patients with systemic rheumatic diseases is the presence of circulating autoantibodies directed against nuclear antigens. The identification of the antigens binding to these antibodies has provided the cell biologist and the immunologist with important tools to study cell structure, cell function, and the processes underlying the immune response. Through the elucidation of autoantibody specificities, the clinician has been provided with a better appreciation of the diagnostic and prognostic significance of autoantibodies. Many autoantigens, including those directed against components in the nuclear matrix, chromosomes, Golgi apparatus, and other intracellular antigens, are not yet characterized nor is their clinical significance established. The mechanisms leading to the breakdown of tolerance and the appearance of autoantibodies are not fully understood. Molecular mimicry at an interspecies or an intracellular level may be involved in altering immune tolerance. On the other hand, studies of epitopes on human autoantigens has provided compelling evidence that most autoantibody responses seen in systemic rheumatic diseases are driven by endogenous antigen.
Similar articles
-
Update on autoantibodies to intracellular antigens in systemic rheumatic diseases.Clin Lab Med. 1992 Mar;12(1):1-23. Clin Lab Med. 1992. PMID: 1563236 Review.
-
The clinical value of intracellular autoantigens B-cell epitopes in systemic rheumatic diseases.Clin Chim Acta. 2004 Feb;340(1-2):1-25. doi: 10.1016/j.cccn.2003.10.011. Clin Chim Acta. 2004. PMID: 14734193 Review.
-
Clinical relevance of autoantibodies in systemic rheumatic diseases.Mol Biol Rep. 1996;23(3-4):133-45. doi: 10.1007/BF00351161. Mol Biol Rep. 1996. PMID: 9112221 Review.
-
Autoantibody testing: procedures and significance in systemic rheumatic diseases.Methods Achiev Exp Pathol. 1986;12:224-60. Methods Achiev Exp Pathol. 1986. PMID: 3083214 Review.
-
AUF1, the regulator of tumor necrosis factor alpha messenger RNA decay, is targeted by autoantibodies of patients with systemic rheumatic diseases.Arthritis Rheum. 2008 Feb;58(2):511-20. doi: 10.1002/art.23306. Arthritis Rheum. 2008. PMID: 18240226
Cited by
-
Molecular characterization of two human autoantigens: unique cDNAs encoding 95- and 160-kD proteins of a putative family in the Golgi complex.J Exp Med. 1993 Jul 1;178(1):49-62. doi: 10.1084/jem.178.1.49. J Exp Med. 1993. PMID: 8315394 Free PMC article.
-
Isolation and characterization of a cartilage-specific membrane antigen (CH65): comparison with cytokeratins and heat-shock proteins.Immunology. 1994 Feb;81(2):322-9. Immunology. 1994. PMID: 7512531 Free PMC article.
-
The major autoantibody epitope on factor H in atypical hemolytic uremic syndrome is structurally different from its homologous site in factor H-related protein 1, supporting a novel model for induction of autoimmunity in this disease.J Biol Chem. 2015 Apr 10;290(15):9500-10. doi: 10.1074/jbc.M114.630871. Epub 2015 Feb 6. J Biol Chem. 2015. PMID: 25659429 Free PMC article.
-
Sera from patients with rheumatic diseases recognize different epitope regions on the 52-kD Ro/SS-A protein.Clin Exp Immunol. 1993 Nov;94(2):227-35. doi: 10.1111/j.1365-2249.1993.tb03436.x. Clin Exp Immunol. 1993. PMID: 7693382 Free PMC article.
-
Chemokine CXCL1 as a potential marker of disease activity in systemic lupus erythematosus.BMC Immunol. 2021 Dec 27;22(1):82. doi: 10.1186/s12865-021-00469-x. BMC Immunol. 2021. PMID: 34961474 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources